Longeveron Inc.
General ticker "LGVN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $20.0M (TTM average)
Longeveron Inc. does not follow the US Stock Market performance with the rate: -35.3%.
Estimated limits based on current volatility of 3.8%: low 1.05$, high 1.14$
Factors to consider:
- Total employees count: 25 (+8.7%) as of 2024
- Top business risk factors: Limited operating history and no commercial products, Geopolitical risks, Operating losses and lack of profitability, Dependence on contract development and manufacturing, Regulatory and compliance
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.40$, 1.38$]
- 2026-12-31 to 2027-12-31 estimated range: [0.36$, 1.23$]
Financial Metrics affecting the LGVN estimates:
- Positive: with PPE of -0.4 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -197.26 <= 0.07
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Inventory ratio change, % of -1.58 <= -0.75
Short-term LGVN quotes
Long-term LGVN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.71MM | $2.39MM | $1.20MM |
| Operating Expenses | $21.74MM | $18.91MM | $24.49MM |
| Operating Income | $-21.03MM | $-16.52MM | $-23.29MM |
| Non-Operating Income | $-0.43MM | $0.55MM | $0.58MM |
| R&D Expense | $9.07MM | $8.14MM | $12.04MM |
| Income(Loss) | $-21.46MM | $-15.97MM | $-22.70MM |
| Profit(Loss)* | $-21.46MM | $-15.97MM | $-22.70MM |
| Stockholders Equity | $6.74MM | $21.89MM | $5.67MM |
| Assets | $12.08MM | $25.56MM | $10.26MM |
| Operating Cash Flow | $-19.00MM | $-13.87MM | $-18.64MM |
| Capital expenditure | $0.30MM | $0.99MM | $0.24MM |
| Investing Cash Flow | $8.19MM | $-0.64MM | $-0.59MM |
| Financing Cash Flow | $5.26MM | $28.79MM | $4.67MM |
| Earnings Per Share** | $-9.87 | $-1.07 | $-1.29 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.